OpenAI has cut off testing access to its Sora video generation platform after a group of artists briefly shared their own early access in a publicly usable webpage Tuesday. The group, going by the moniker PR Puppets, claims the stunt was a protest against being asked to work as unpaid R&D and bug testers while participating in "art washing" of AI tools. But OpenAI says participation in the early alpha test is voluntary and has no requirements that testers provide feedback.

PR Puppets posted its "Generate with Sora" access point to Hugging Face at about 8:30 Eastern time Tuesday morning, according to Git commit logs. Quickly, AI experts on social media noticed the posting and confirmed that the page connected to endpoints on OpenAI's actual Sora API and hosting on a videos.openai.com domain, presumably with authentication tokens provided to testers by OpenAI itself.

OMG OpenAI Sora has been leaked!

Free to use now on Huggingface, link in comment

It can be shut down anytime, try it now! It can generate 1080P and up to 10s video! And the results are incredible!

9 Examples: pic.twitter.com/rIJJv5TQTo

— el.cine (@EHuanglu) November 26, 2024

That access was revoked within hours, but not before plenty of eager followers managed to generate their own videos and share them on social media . An OpenAI spokesperson told The Washington Post the company is temporarily pausing all test access to Sora to evaluate the situation. Other users dug into the code to discover hints of different modes and "styles" that might be in development for Sora.

Read full article

Comments

OpenAI has cut off testing access to its Sora video generation platform after a group of artists briefly shared their own early access in a publicly usable webpage Tuesday. The group, going by the moniker PR Puppets, claims the stunt was a protest against being asked to work as unpaid R&D and bug testers while participating in "art washing" of AI tools. But OpenAI says participation in the early alpha test is voluntary and has no requirements that testers provide feedback.

PR Puppets posted its "Generate with Sora" access point to Hugging Face at about 8:30 Eastern time Tuesday morning, according to Git commit logs. Quickly, AI experts on social media noticed the posting and confirmed that the page connected to endpoints on OpenAI's actual Sora API and hosting on a videos.openai.com domain, presumably with authentication tokens provided to testers by OpenAI itself.

OMG OpenAI Sora has been leaked!

Free to use now on Huggingface, link in comment

It can be shut down anytime, try it now! It can generate 1080P and up to 10s video! And the results are incredible!

9 Examples: pic.twitter.com/rIJJv5TQTo

— el.cine (@EHuanglu) November 26, 2024

That access was revoked within hours, but not before plenty of eager followers managed to generate their own videos and share them on social media . An OpenAI spokesperson told The Washington Post the company is temporarily pausing all test access to Sora to evaluate the situation. Other users dug into the code to discover hints of different modes and "styles" that might be in development for Sora.

Read full article

Comments

OpenAI has cut off testing access to its Sora video generation platform after a group of artists briefly shared their own early access in a publicly usable webpage Tuesday. The group, going by the moniker PR Puppets, claims the stunt was a protest against being asked to work as unpaid R&D and bug testers while participating in "art washing" of AI tools. But OpenAI says participation in the early alpha test is voluntary and has no requirements that testers provide feedback.

PR Puppets posted its "Generate with Sora" access point to Hugging Face at about 8:30 Eastern time Tuesday morning, according to Git commit logs. Quickly, AI experts on social media noticed the posting and confirmed that the page connected to endpoints on OpenAI's actual Sora API and hosting on a videos.openai.com domain, presumably with authentication tokens provided to testers by OpenAI itself.

OMG OpenAI Sora has been leaked!

Free to use now on Huggingface, link in comment

It can be shut down anytime, try it now! It can generate 1080P and up to 10s video! And the results are incredible!

9 Examples: pic.twitter.com/rIJJv5TQTo

— el.cine (@EHuanglu) November 26, 2024

That access was revoked within hours, but not before plenty of eager followers managed to generate their own videos and share them on social media . An OpenAI spokesperson told The Washington Post the company is temporarily pausing all test access to Sora to evaluate the situation. Other users dug into the code to discover hints of different modes and "styles" that might be in development for Sora.

Read full article

Comments

Google got some disappointing news at a status conference Tuesday, where US District Judge Amit Mehta suggested that Google's AI products may be restricted as an appropriate remedy following the government's win in the search monopoly trial.

According to Law360 , Mehta said that "the recent emergence of AI products that are intended to mimic the functionality of search engines" is rapidly shifting the search market. Because the judge is now weighing preventive measures to combat Google's anticompetitive behavior, the judge wants to hear much more about how each side views AI's role in Google's search empire during the remedies stage of litigation than he did during the search trial.

"AI and the integration of AI is only going to play a much larger role, it seems to me, in the remedy phase than it did in the liability phase," Mehta said. "Is that because of the remedies being requested? Perhaps. But is it also potentially because the market that we have all been discussing has shifted?"

Read full article

Comments

Google got some disappointing news at a status conference Tuesday, where US District Judge Amit Mehta suggested that Google's AI products may be restricted as an appropriate remedy following the government's win in the search monopoly trial.

According to Law360 , Mehta said that "the recent emergence of AI products that are intended to mimic the functionality of search engines" is rapidly shifting the search market. Because the judge is now weighing preventive measures to combat Google's anticompetitive behavior, the judge wants to hear much more about how each side views AI's role in Google's search empire during the remedies stage of litigation than he did during the search trial.

"AI and the integration of AI is only going to play a much larger role, it seems to me, in the remedy phase than it did in the liability phase," Mehta said. "Is that because of the remedies being requested? Perhaps. But is it also potentially because the market that we have all been discussing has shifted?"

Read full article

Comments

Google got some disappointing news at a status conference Tuesday, where US District Judge Amit Mehta suggested that Google's AI products may be restricted as an appropriate remedy following the government's win in the search monopoly trial.

According to Law360 , Mehta said that "the recent emergence of AI products that are intended to mimic the functionality of search engines" is rapidly shifting the search market. Because the judge is now weighing preventive measures to combat Google's anticompetitive behavior, the judge wants to hear much more about how each side views AI's role in Google's search empire during the remedies stage of litigation than he did during the search trial.

"AI and the integration of AI is only going to play a much larger role, it seems to me, in the remedy phase than it did in the liability phase," Mehta said. "Is that because of the remedies being requested? Perhaps. But is it also potentially because the market that we have all been discussing has shifted?"

Read full article

Comments

The Biden administration on Tuesday issued sweeping health care proposals that would see Medicare plans greatly expand access to blockbuster GLP-1 weight-loss drugs, bar insurers from skipping out on paying certain claims that were granted prior authorization, and reinforce guardrails on the use of AI.

The proposals fit into the administration's existing aims to improve and protect access to care in Medicare and Medicaid programs. But, the future of the proposals is uncertain, as it will be up to the Trump administration to finalize the policies.

Anti-obesity drugs

The flashiest of the proposals is to reinterpret existing law in such a way as to allow Medicare and Medicaid coverage of anti-obesity drugs—particularly the extremely popular and pricy GLP-1 drugs Wegovy and Zepbound. Existing policy excludes coverage of drugs used for "weight loss" or "weight gain."

Read full article

Comments

The Biden administration on Tuesday issued sweeping health care proposals that would see Medicare plans greatly expand access to blockbuster GLP-1 weight-loss drugs, bar insurers from skipping out on paying certain claims that were granted prior authorization, and reinforce guardrails on the use of AI.

The proposals fit into the administration's existing aims to improve and protect access to care in Medicare and Medicaid programs. But, the future of the proposals is uncertain, as it will be up to the Trump administration to finalize the policies.

Anti-obesity drugs

The flashiest of the proposals is to reinterpret existing law in such a way as to allow Medicare and Medicaid coverage of anti-obesity drugs—particularly the extremely popular and pricy GLP-1 drugs Wegovy and Zepbound. Existing policy excludes coverage of drugs used for "weight loss" or "weight gain."

Read full article

Comments

The Biden administration on Tuesday issued sweeping health care proposals that would see Medicare plans greatly expand access to blockbuster GLP-1 weight-loss drugs, bar insurers from skipping out on paying certain claims that were granted prior authorization, and reinforce guardrails on the use of AI.

The proposals fit into the administration's existing aims to improve and protect access to care in Medicare and Medicaid programs. But, the future of the proposals is uncertain, as it will be up to the Trump administration to finalize the policies.

Anti-obesity drugs

The flashiest of the proposals is to reinterpret existing law in such a way as to allow Medicare and Medicaid coverage of anti-obesity drugs—particularly the extremely popular and pricy GLP-1 drugs Wegovy and Zepbound. Existing policy excludes coverage of drugs used for "weight loss" or "weight gain."

Read full article

Comments